RT Journal Article
T1 Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.
A1 Cariolou, Margarita
A1 Christakoudi, Sofia
A1 Gunter, Marc J
A1 Key, Tim
A1 Pérez-Cornago, Aurora
A1 Travis, Ruth
A1 Zamora-Ros, Raul
A1 Petersen, Kristina Elin T
A1 Tjønneland, Anne
A1 Weiderpass, Elisabete
A1 Kaaks, Rudolf
A1 Seibold, Petra
A1 Inan-Eroglu, Elif
A1 Schulze, Matthias B
A1 Masala, Giovanna
A1 Agnoli, Claudia
A1 Tumino, Rosario
A1 Di Girolamo, Chiara
A1 Aizpurua, Amaia
A1 Rodriguez-Barranco, Miguel
A1 Santiuste, Carmen
A1 Guevara, Marcela
A1 Aune, Dagfinn
A1 Chan, Doris S M
A1 Muller, David C
A1 Tsilidis, Konstantinos K
K1 Adiposity
K1 Association
K1 Body Mass Index
K1 Diagnosis
K1 Disease
K1 History
K1 Interleukin-10
K1 Interleukin-6
AB Background: Adiposity has been characterized as a modifiable risk factor for prostate cancer. Its association with outcomes after prostate cancer diagnosis, however, must be better understood, and more evidence is needed to facilitate the development of lifestyle guidance for patients with prostate cancer.Methods: We investigated the associations between adiposity indices close to prostate cancer diagnosis (up to 2 years before or up to 5 years after diagnosis) and mortality in 1968 men of the European Prospective Investigation into Cancer and Nutrition cohort. Men were followed up for a median of 9.5 years. Cox proportional hazards models were adjusted for age and year of diagnosis, disease stage and grade, and smoking history and stratified by country.Results: Each 5-unit increment in prediagnosis or postdiagnosis body mass index combined was associated with a 30% higher rate of all-cause mortality and a 49% higher rate of prostate cancer-specific mortality. Similarly, each 5-unit increment in prediagnosis body mass index was associated with a 35% higher rate of all-cause mortality and a 51% higher rate of prostate cancer-specific mortality. The associations were less strong for postdiagnosis body mass index, with a lower number of men in analyses. Less clear positive associations were shown for waist circumference, hip circumference, and waist to hip ratio, but data were limited.Conclusions: Elevated levels of adiposity close to prostate cancer diagnosis could lead to higher risk of mortality; therefore, men are encouraged to maintain a healthy weight. Additional research is needed to confirm whether excessive adiposity after prostate cancer diagnosis could worsen prognosis.
PB Oxford University Press
YR 2024
FD 2024-09-02
LK https://hdl.handle.net/10668/24323
UL https://hdl.handle.net/10668/24323
NO Cariolou M, Christakoudi S, Gunter MJ, Key T, Pérez-Cornago A, Travis R, et al. Adiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study. JNCI Cancer Spectr. 2024 Sep 2;8(5):pkae070
NO This work was supported by the World Cancer Research Fund network of charities (American Institute for Cancer Research, World Cancer Research Fund, and Wereld Kanker Onderzoek Fonds). The coordination of EPIC is financially supported the International Agency for Research on Cancer and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the National Institute for Health and Care Research Imperial Biomedical Research Centre. The national cohorts are supported by the Danish Cancer Society; German Cancer Aid, German Cancer Research Center, German Institute of Human Nutrition Potsdam-Rehbruecke, Federal Ministry of Education and Research (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo, and National Research Council (Italy); Health Research Fund, Institute of Health Carlos III, and the regional governments of Andaluc�ıa, Asturias, Basque Country, Murcia, and Navarra, and the Catalan Institute of Oncology (Spain); and Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (MR/N003284/1, MCUU_12015/1 and MC_UU_00006/1 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). R. Zamora-Ros was supported by the Miguel Servet II (CPII20/ 00009) program from Institute of Health Carlos III (co-funded by the European Social Fund investing in your future). The open access fee was paid from the Imperial College London Open Access Fund.
DS RISalud
RD Apr 7, 2025